EA201891023A1 - Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции - Google Patents

Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции

Info

Publication number
EA201891023A1
EA201891023A1 EA201891023A EA201891023A EA201891023A1 EA 201891023 A1 EA201891023 A1 EA 201891023A1 EA 201891023 A EA201891023 A EA 201891023A EA 201891023 A EA201891023 A EA 201891023A EA 201891023 A1 EA201891023 A1 EA 201891023A1
Authority
EA
Eurasian Patent Office
Prior art keywords
abeksinostat
preparation
pharmaceutical compositions
crystal form
corresponding crystal
Prior art date
Application number
EA201891023A
Other languages
English (en)
Other versions
EA039113B1 (ru
Inventor
Анне Пимон-Гарро
Филипп Летельер
Original Assignee
Фармасайкликс Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201891023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармасайкликс Элэлси filed Critical Фармасайкликс Элэлси
Publication of EA201891023A1 publication Critical patent/EA201891023A1/ru
Publication of EA039113B1 publication Critical patent/EA039113B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Abstract

Тозилат абексиностата формулы (II)и его кристаллическая форма I, которые характеризуются их рентгеновской порошковой дифрактограммой, рамановским спектром и твердотельным ЯМР-спектромС CP/MAS.
EA201891023A 2013-03-04 2014-03-03 Композиция кристаллической формы i тозилата абексиностата, способ ее получения и применение для лечения рака EA039113B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EA201891023A1 true EA201891023A1 (ru) 2019-03-29
EA039113B1 EA039113B1 (ru) 2021-12-06

Family

ID=48521256

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591530A EA030689B1 (ru) 2013-03-04 2014-03-03 Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
EA201891023A EA039113B1 (ru) 2013-03-04 2014-03-03 Композиция кристаллической формы i тозилата абексиностата, способ ее получения и применение для лечения рака

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201591530A EA030689B1 (ru) 2013-03-04 2014-03-03 Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции

Country Status (39)

Country Link
US (3) US9115108B2 (ru)
EP (2) EP2964622B1 (ru)
JP (2) JP6449177B2 (ru)
CN (2) CN109734690B (ru)
AR (1) AR094935A1 (ru)
AU (2) AU2014224456B2 (ru)
BR (1) BR112015021443A2 (ru)
CA (1) CA2903369C (ru)
CL (1) CL2015002488A1 (ru)
CR (1) CR20150456A (ru)
CY (1) CY1119147T1 (ru)
DK (1) DK2964622T3 (ru)
DO (1) DOP2015000215A (ru)
EA (2) EA030689B1 (ru)
ES (1) ES2632471T3 (ru)
FR (1) FR3002733B1 (ru)
GE (1) GEP201706760B (ru)
HK (1) HK1220965A1 (ru)
HR (1) HRP20171041T1 (ru)
HU (1) HUE035299T2 (ru)
IL (1) IL241038B (ru)
JO (1) JO3402B1 (ru)
LT (1) LT2964622T (ru)
MA (1) MA38423B1 (ru)
ME (1) ME02814B (ru)
MX (1) MX355436B (ru)
MY (1) MY192027A (ru)
NI (1) NI201500122A (ru)
PE (1) PE20151591A1 (ru)
PL (1) PL2964622T3 (ru)
PT (1) PT2964622T (ru)
RS (1) RS56224B1 (ru)
SG (1) SG11201506952YA (ru)
SI (1) SI2964622T1 (ru)
TN (1) TN2015000367A1 (ru)
TW (1) TWI506023B (ru)
UA (1) UA118550C2 (ru)
UY (1) UY35356A (ru)
WO (1) WO2014135776A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
JP6178861B2 (ja) 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2960044A1 (en) * 2014-09-03 2016-03-10 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
BRPI0409227C1 (pt) * 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2964622T (pt) 2017-07-13
FR3002733B1 (fr) 2015-08-14
CN109734690B (zh) 2023-08-11
UA118550C2 (uk) 2019-02-11
DK2964622T3 (en) 2017-07-31
GEP201706760B (en) 2017-10-25
AU2014224456A8 (en) 2015-10-22
CA2903369A1 (en) 2014-09-12
US10150748B2 (en) 2018-12-11
EP2964622A1 (fr) 2016-01-13
US20140249215A1 (en) 2014-09-04
JP6720280B2 (ja) 2020-07-08
EA030689B1 (ru) 2018-09-28
DOP2015000215A (es) 2015-09-30
SG11201506952YA (en) 2015-10-29
TN2015000367A1 (fr) 2017-01-03
MX355436B (es) 2018-04-18
CN105263917B (zh) 2018-11-20
EP2964622B1 (fr) 2017-04-19
JO3402B1 (ar) 2019-10-20
HRP20171041T1 (hr) 2017-10-06
WO2014135776A1 (fr) 2014-09-12
JP6449177B2 (ja) 2019-01-09
AR094935A1 (es) 2015-09-09
FR3002733A1 (fr) 2014-09-05
UY35356A (es) 2014-09-30
EP3252044A1 (fr) 2017-12-06
ME02814B (me) 2018-01-20
BR112015021443A2 (pt) 2017-07-18
AU2014224456A1 (en) 2015-10-08
CN105263917A (zh) 2016-01-20
TW201434822A (zh) 2014-09-16
US9115108B2 (en) 2015-08-25
JP2019069955A (ja) 2019-05-09
CL2015002488A1 (es) 2016-03-11
NI201500122A (es) 2018-10-18
RS56224B1 (sr) 2017-11-30
US20170313671A1 (en) 2017-11-02
AU2014224456B2 (en) 2018-01-25
CY1119147T1 (el) 2018-02-14
NZ712380A (en) 2020-10-30
SI2964622T1 (sl) 2017-10-30
AU2018202881A1 (en) 2018-05-17
PL2964622T3 (pl) 2017-10-31
EA201591530A1 (ru) 2016-01-29
MX2015011566A (es) 2016-06-24
ES2632471T3 (es) 2017-09-13
US20150315167A1 (en) 2015-11-05
MA38423B1 (fr) 2017-10-31
JP2016510735A (ja) 2016-04-11
HK1220965A1 (zh) 2017-05-19
HUE035299T2 (en) 2018-05-02
AU2018202881B2 (en) 2020-02-27
LT2964622T (lt) 2017-08-10
EA039113B1 (ru) 2021-12-06
CA2903369C (en) 2021-06-08
IL241038B (en) 2019-09-26
IL241038A0 (en) 2015-11-30
TWI506023B (zh) 2015-11-01
PE20151591A1 (es) 2015-11-06
MY192027A (en) 2022-07-23
MA38423A1 (fr) 2017-02-28
CN109734690A (zh) 2019-05-10
CR20150456A (es) 2015-10-21

Similar Documents

Publication Publication Date Title
EA201891023A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
MX2015014470A (es) Analogos de combretastatina.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
EA201591449A1 (ru) Способы получения противораковых композиций
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina
UA112146C2 (uk) Спосіб отримання 4,1-бензоксатієпін-3-ону